We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+13.8%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$14.5B
AUM Growth
+$1.96B
Cap. Flow
+$582M
Cap. Flow %
4.02%
Top 10 Hldgs %
31.8%
Holding
146
New
31
Increased
52
Reduced
23
Closed
24

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$319M
2
IMMU
Immunomedics Inc
IMMU
+$296M
3
GOOG icon
Alphabet (Google) Class C
GOOG
+$216M
4
NYT icon
New York Times
NYT
+$130M
5
HLT icon
Hilton Worldwide
HLT
+$129M

Top Sells

Rank Stock Value
1
PPLI
People Inc
PPLI
+$456M
2
WUBA
58.com Inc
WUBA
+$268M
3
CRM icon
Salesforce
CRM
+$181M
4
QGEN icon
Qiagen
QGEN
+$123M
5
CZR
Caesars Entertainment Corporation
CZR
+$97.2M

Sector Composition

Rank Sector Weight
1 Healthcare 44.6%
2 Communication Services 17.58%
3 Technology 8.94%
4 Financials 7.39%
5 Industrials 5.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLGX
76
DELISTED
Corelogic, Inc.
CLGX
$23.3M 0.16%
+345,000
New +$23.2M
BEKE icon
77
KE Holdings
BEKE
$19.6B
$20.5M 0.14%
+335,000
New +$16.7M
KRYS icon
78
Krystal Biotech
KRYS
$10.3B
$20.4M 0.14%
475,000
+25,000
+6% +$1.09M
ADAP
79
DELISTED
Adaptimmune Therapeutics
ADAP
$20.1M 0.14%
2,515,762
+15,762
+0.6% +$138K
ZEAL
80
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$19.2M 0.13%
505,000
+5,000
+1% +$181K
ARWR icon
81
Arrowhead Research
ARWR
$12.3B
$18.2M 0.13%
423,600
-376,400
-47% -$16.2M
PLRX icon
82
Pliant Therapeutics
PLRX
$71.8M
$17.3M 0.12%
764,262
-86,539
-10% -$2.16M
DCPH
83
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$16.9M 0.12%
330,000
-385,000
-54% -$18.9M
QURE icon
84
uniQure
QURE
$3.36B
$16.6M 0.11%
450,000
+150,000
+50% +$6.15M
ADVM
85
DELISTED
Adverum Biotechnologies
ADVM
$15.4M 0.11%
+150,000
New +$22.5M
RC
86
Ready Capital
RC
$311M
$15.1M 0.1%
1,350,226
– –
AUPH icon
87
Aurinia Pharmaceuticals
AUPH
$2.22B
$14.7M 0.1%
+1,000,000
New +$14.5M
DMTK
88
DELISTED
DermTech, Inc. Common Stock
DMTK
$14.6M 0.1%
1,219,999
+1,025,324
+527% +$11.9M
TECX
89
Tectonic Therapeutic
TECX
$736M
$13.7M 0.09%
87,500
-43,750
-33% -$8.81M
CMPS
90
Compass Pathways
CMPS
$1.85B
$12.7M 0.09%
+362,940
New +$13M
NAV
91
DELISTED
Navistar International
NAV
$12M 0.08%
+276,600
New +$9.49M
ATTO
92
DELISTED
Atento S.A.
ATTO
$12M 0.08%
2,230,357
– –
HZNP
93
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$11.7M 0.08%
+150,000
New +$10.3M
WTW icon
94
Willis Towers Watson
WTW
$31.8B
$10.4M 0.07%
+50,000
New +$10.2M
RCUS icon
95
Arcus Biosciences
RCUS
$3.86B
$9.43M 0.07%
550,000
-450,000
-45% -$10.1M
LQDA icon
96
Liquidia Corp
LQDA
$6.14B
$9.18M 0.06%
1,865,350
+15,350
+0.8% +$88.8K
TARA icon
97
Protara Therapeutics
TARA
$228M
$7.15M 0.05%
+425,000
New +$9.86M
INBX
98
DELISTED
Inhibrx, Inc. Common Stock
INBX
$7.11M 0.05%
+395,000
New +$7.16M
ALBO
99
DELISTED
Albireo Pharma Inc
ALBO
$6.67M 0.05%
+200,000
New +$5.83M
ALPN
100
DELISTED
Alpine Immune Sciences Inc
ALPN
$6.52M 0.05%
+741,290
New +$6.78M
2 3
4
5 6

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q3 2020 Portfolio in Review

As of Q3 2020, Thomas Steyer held 146 positions worth $14.5B, up 16% from $12.5B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Thomas Steyer deployed $582M of net new capital in Q3 2020, opening 31 new positions and adding to 52 existing holdings. Its largest new stake was Boston Scientific: 8,275,919 shares worth $316M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, up from 43% a quarter earlier, followed by Communication Services and Technology.

On the sell side, the largest reduction was Salesforce, an estimated $181M trimmed.

  • Thomas Steyer's largest Q3 2020 buy was Boston Scientific: 8,275,919 shares worth $316M.
  • Thomas Steyer added most to Alphabet (Google) Class C in Q3 2020, an estimated $216M increase.
  • Thomas Steyer's biggest Q3 2020 reduction was Salesforce, cutting an estimated $181M.
  • Thomas Steyer fully exited People Inc in Q3 2020, selling an estimated $456M.
  • Thomas Steyer's ten largest holdings make up 32% of its $14.5B portfolio in Q3 2020.
  • Thomas Steyer opened 31 new positions and closed 24 in Q3 2020.
  • Thomas Steyer's portfolio value rose 16% quarter-over-quarter to $14.5B.

Based on Farallon Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.